Serum Pre-Clinical CartiLaps® (CTX-II) EIA

Product Description

For determination of degradation products of C-terminal telopeptides of type II collagen (CTX-II) in animal serum.

Assessment in animal models of Rheumatoid Arthritis and Osteoarthritis
Allows easy, non-invasive quantification of cartilage degradation
Demonstrates: – strong association to indexes of joint damage, e.g. cartilage erosion, – Effect of chondroprotective drugs, – Rapid response (1-2 weeks) to chondroprotective drugs
Early response in CTX-II is highly correlated to histological endpoints¹
CTX-II is elevated in both RA and OA rat models
CTX-II levels are associated with disease activity in RA and OA, primarily indexes of structural damage²
Useful for dynamic monitoring of cartilage in multiple species
Part of a complete assay panel supporting bone and cartilage research

1. Nielsen RH et al., Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover. Osteoarthritis Cartilage. 2011 Apr;19(4):466-73.
2. Oestergaard S et al., The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Osteoarthritis Cartilage. 2006 Jul;14(7):670-9.
3. Schaller S et al., In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol. 2005 Oct;3(5):553-80.

Assays	Certification	Platform	Clinical Area	Portfolio	RUO/IVD
Urine CartiLaps® (CTX-II) EIA	510 (k) exemptCE Marked		Cartilage Markers	Endocrinology	IVD
Human COMP ELISA	CE Marked		Cartilage Markers	Endocrinology	IVD